

GOSHEN
Cancer Incidence by Sex, 1993 - 1997
Expected and Observed Case Counts, with Standardized Incidence Ratios

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---------------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 0.67 | 0 | NC* | Male | 0.38 | 0 | NC* |
| Female | 0.19 | 0 | NC* | Female | 0.26 | 0 | NC* |
| Total | 0.86 | 0 | NC* | Total | 0.64 | 0 | NC* |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 0.20 | 2 | NC* | Male | 0.12 | 0 | NC* |
| Female | 0.15 | 1 | NC* | Female | 0.09 | 0 | NC* |
| Total | 0.35 | 3 | NC* | Total | 0.21 | 0 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.04 | 0 | NC* | Male | 0.51 | 1 | NC* |
| Female | 3.22 | 2 | NC* | Female | 0.37 | 0 | NC* |
| Total | 3.26 | 2 | NC* | Total | 0.87 | 1 | NC* |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 0.22 | 0 | NC* | Male | 0.42 | 1 | NC* |
| | | | | Female | 0.16 | 0 | NC* |
| | | | | Total | 0.59 | 1 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 1.69 | 2 | NC* | Female | 0.39 | 0 | NC* |
| Female | 1.23 | 0 | NC* | | | | |
| Total | 2.91 | 2 | NC* | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.24 | 0 | NC* | Male | 0.25 | 0 | NC* |
| Female | 0.06 | 0 | NC* | Female | 0.20 | 0 | NC* |
| Total | 0.30 | 0 | NC* | Total | 0.45 | 0 | NC* |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 0.09 | 0 | NC* | Male | 4.06 | 1 | NC* |
| Female | 0.07 | 0 | NC* | | | | |
| Total | 0.16 | 0 | NC* | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 0.37 | 0 | NC* | Male | 0.29 | 0 | NC* |
| Female | 0.18 | 0 | NC* | Female | 0.13 | 0 | NC* |
| Total | 0.55 | 0 | NC* | Total | 0.42 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.23 | 0 | NC* | Male | 0.13 | 0 | NC* |

| | | | | | | | |
|---|------|---|-----|---|-------|----|-----|
| Female | 0.05 | 0 | NC* | | | | |
| Total | 0.28 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.28 | 0 | NC* | Male | 0.07 | 0 | NC* |
| Female | 0.17 | 0 | NC* | Female | 0.18 | 0 | NC* |
| Total | 0.45 | 0 | NC* | Total | 0.25 | 0 | NC* |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Male | 0.13 | 0 | NC* | | | | |
| Female | 0.04 | 0 | NC* | Female | 0.61 | 3 | NC* |
| Total | 0.17 | 0 | NC* | | | | |
| <u>Lung and Bronchus</u> | | | | <u>All Sites / Types</u> | | | |
| Male | 2.12 | 2 | NC* | Male | 13.20 | 9 | 68 |
| Female | 1.24 | 2 | NC* | Female | 9.93 | 8 | 81 |
| Total | 3.36 | 4 | NC* | Total | 23.13 | 17 | 73 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.05$ and $p \leq 0.01$ levels